'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo Finance
Portfolio Pulse from Benzinga Newsdesk
The U.S. Supreme Court declined to hear Vanda Pharmaceuticals' appeal to revive patents for Hetlioz, a sleep-disorder drug, after they were declared invalid in a dispute with Teva and Apotex. The patents were invalidated by the U.S. Court of Appeals for the Federal Circuit, which upheld a decision based on the obviousness of the patents. Vanda's sales of Hetlioz exceeded $100 million in 2023. The decision allows Teva and Apotex to proceed with generic versions of the drug.
April 22, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The Supreme Court's decision not to hear Vanda Pharmaceuticals' appeal on Hetlioz patents could negatively impact its stock price due to potential competition from generics.
The refusal by the Supreme Court to revive Vanda's patents for Hetlioz opens the door for generic versions by Teva and Apotex, potentially reducing Vanda's market share and revenue from Hetlioz, which is a significant product for the company with sales over $100 million in 2023.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Teva may see a positive short-term impact on its stock price as the Supreme Court's decision allows it to proceed with generic versions of Hetlioz.
The clearance to produce generic versions of Hetlioz could lead to increased revenue streams for Teva, enhancing its competitive position in the market for sleep-disorder treatments.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70